Apogee Therapeutics (APGE) Corporate presentation summary

Strategic vision and market opportunity

• Focus on delivering transformative therapies for atopic dermatitis (AD) and other inflammatory and immunological (I&I) diseases, targeting large and rapidly growing markets with unmet needs.

• Projected AD market growth from ~$18B to over $50B by 2030, with biologic penetration expected to rise significantly.

• Late-stage development in AD and asthma, with plans for expansion into additional dermatology, respiratory, and gastrointestinal indications.

• Well-capitalized with $903M in cash and runway into 2H 2028 to support clinical milestones and pipeline advancement.

Pipeline highlights and clinical progress

• Zumilokibart (APG777) is advancing toward a planned 2029 launch, offering every 3- to 6-month dosing and aiming for best-in-class efficacy and safety.

• Phase 2 Part A demonstrated strong efficacy and rapid itch relief, with maintenance dosing potentially reducing annual injections from 26 (DUPIXENT) to 2–4.

• Phase 2 Part B completed enrollment (N=347), with a Q2 2026 readout to inform Phase 3 dose selection and initiation.

• Positive Phase 1b asthma data showed durable FeNO suppression, supporting expansion into respiratory indications.

Differentiation and competitive positioning

• Zumilokibart aims to match or exceed DUPIXENT’s efficacy with less frequent dosing, potentially transforming the standard of care in AD.

• Rapid, deep itch relief observed, comparable to NEMLUVIO + TCS, and lesion control similar to leading biologics.

• High physician and patient preference: 60% of surveyed physicians would choose zumilokibart as their top biologic for AD.

• Combination therapies (APG279, APG273) leveraging validated mechanisms are advancing, with APG279 in a head-to-head trial against DUPIXENT.